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The prognostic significance of transforming growth factors in human
breast cancer
P.A. Murray' 2, P. Barrett-Lee', M. Travers', Y. Luqmanil, T. Powles2 & R.C. Coombes'
'Department ofMedical Oncology, St Georges Hospital, Blackshaw Road, London, SW17 ORE and the 'Medical Breast Unit, The
Royal Marsden Hospital, Sutton, Surrey, UK.
Summary Transforming growth factor alpha (TGFa) and Transforming growth factor beta-I (TGF-P,) are
growth regulatory for breast cancer cell lines in vitro and several studies have suggested that levels of the
receptor for TGFa, the epidermal growth factor (EGFR) in tumour biopsies predict relapse and survival. We
have examined the prognostic significance of TGFax, TGF-P, and EGFR mRNA expression in a series of
patients with primary breast cancer with a median follow up period of 60 months. In 167 patients the
expression ofTGF-P, was inversely correlated with node status (P = 0.065) but not ER status, tumour size or
menopausal status. Patients with high levels of TGF-P, had a longer disease free interval with a significantly
longer probability of survival at 80 months although the overall relapse free survival was not increased. EGFR
mRNA expression was measured in 106 patients and was inversely correlated with ER status (P = 0.018).
EGFR levels did not predict for early relapse or survival. TGFa mRNA levels were measured in 104 patients,
no correlation was seen tumour size, node status, Er status, or clinical outcome.
The growth of breast cancer cells is regulated by numerous
peptide growth factors including transforming growth factor
alpha (TGF-alpha) (Salomon et al., 1984) and transforming
growth factor beta-I (TGF-PI) (Knabbe et al., 1987). As
breast cancer cells express both the receptor and the ligand
for numerous growth factors it has been suggested that an
autocrine loop might be an important mechanism of growth
regulation for breast cancer in vivo (Sporn & Todaro, 1980).
TGF-alpha is a 50 amino acid peptide which binds to the
Epidermal growth factor receptor (EGFR) and is mitogenic
for breast cancer cell lines in vitro. TGF-alpha has a more
profound and prolonged action on EGFR than Epidermal
growth factor itself. It has been reported that TGF alpha
synthesis is regulated both in vitro (Bates et al., 1988) and in
vivo (Lui et al., 1987) by oestrogens suggesting a possible role
in mediating the effect of endocrine therapy. The importance
of a possible autocrine loop in breast cancer involving TGF-
alpha is suggested by several studies that have shown a
correlation between high levels of EGFR in tumour biopsies
and early relapse and survival (Toi et al., 1990; Lewis et al.,
1990; Grimaux et al., 1989; Rios et al., 1988; Sainsbury et al.,
1987).
The TGF-betas are a family of multifunctional growth
factors. The best characterised of these peptides is TGF-P,
which is a 25 kDa homodimer which is synthesised by a wide
variety of both normal and malignant cells (Derynck et al.,
1985). TGF-P, has multiple actions including both
stimulatory and inhibitory effects on cell growth although its
predominant effect on epithelial cells is inhibitory. It has
effects on cellular differentiation, is a chemotactic agent and
has numerous effects on extracellular matrix control (Sporn
& Roberts, 1989). It has been reported that members of the
TGF beta family are regulated in vitro by oestrogen (Arrick
et al., 1990) and that the anti-oestrogen Tamoxifen increases
secretion of locally active TGF beta from breast cancer cells
(Knabbe et al., 1987) and stromal fibroblasts (Colletta et al.,
1990).
In our preliminary studies of mRNA transcripts of TGF
alpha, EGFR and TGF-P1 in 69 breast carcinomas with a
short follow up of 42.5 months, we found TGF alpha,
EGFR, TGF-P1 transcripts in 42%, 55% and 100% of
tumours respectively and an inverse correlation of EGFR
with ER status but, as expected with such a small number of
patients and short follow up, no correlation of EGFR, TGF-
PI or TGF alpha with prognosis (Barrett-Lee et al.,
1990).
We have now extended our observations of clinical cor-
relates with transcript levels of TGF alpha, TGF-P, and
EGFR to a larger series of patients with a median follow up
time of 60 months.
Materials and methods
Patients and samples
Breast samples were obtained from the tissue bank kept at
the Department of Medical Oncology, St Georges Hospital.
In recent years samples have been sent here routinely from
several centres for oestrogen receptor analysis after being
immediately frozen in liquid nitrogen after resection.
Samples were selected at random from the tissue bank
providing the samples had been deposited 5 years previously.
They were resected between 1978 and 1984 from patients
aged between 36 and 90 years (mean age 62). The clinical
details were then obtained from the patients notes. The histo-
logical types were infiltrating ductal carcinoma in 149 cases.
In addition 11 were lobular carcinomas, two colloid and one
medullary carcinomas. Details of T stage and node status
were retrospectively extracted from the notes. Any patients
found to have another malignancy or a previous breast car-
cinoma were excluded. Patients who developed a second
breast carcinoma were censored at the time of presentation of
the second malignancy. The time to relapse was defined as
the period from primary surgery to the development of
metastatic disease. Patients who relapsed only locally were
not considered to have relapsed as local relapse may depend
more on the type of primary local therapy administered
rather than the biology of the tumour. The median duration
of follow up was 60 months (range 6 to 119 months).
cDNA probes
The complementary DNA (cDNA) sequences encoding
EGFR (Ullrich et al., 1984), TGF alpha (Derynck et al.,
1984), TGF-P1 (Derynck et al., 1985) and beta-Actin (Ponte
et al., 1984) were excised from plasmids and labelled with
alpha-32P-dCTP (Amersham, UK) by the random primer
method (Feinberg & Vogelstein, 1983).
Total cellular RNA was extracted from 0.5-1 gm of frozen
tissue as previously described (Chirgwin et al., 1979). In 10
cases polyadenylated (Poly(A)+) mRNA was obtained by one
passage through oligo (dT) cellulose (Aviv & Leder,
1972).
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To assess the integrity of the RNA extracted all samples
were fractionated on Loening phosphategels (Loening &
Ingle, 1967) prior to dot-blot analysis. Samples showing
evidence of degradation by loss of clear ribosomal bands
were discarded. This also served as a check of the concentra-
tion of RNA loaded as equal amounts of RNA loaded would
fluoresce equally under UV illumination.
For dot blot analysis serial dilutions of denatured RNA
were applied to Hybond membranes (Amersham, UK) using
a Bio-Dot apparatus (Bio-Rad, UK) as previously described
(Barrett-Lee et al., 1987). Serial dilutions of the plasmid
being studied and of non-homologous RNA were applied to
the membrane to quantify the signal and assess the extent of
non-specific hybridisation. For each cDNA probe several
tumour samples were analysed by Northern blotting to assess
transcript size. For northern analysis (Thomas, 1980) 2.5 ,.g
poly (A)' or 20jig total mRNA per sample were resolved in
a formaldehyde/agarose gel and blotted onto Hybond-N
membrane. Denatured RNA markers were also run to enable
sizing of hybridising bands.
Filters were prehybridised at 42°C for 4 h in 50%
deionised formamide, 0.1% sodium dodecyl sulphate (SDS),
5 x Denhart's solution (1 x Denhart's = 0.02% each of
polyvinylpyrrolidine, bovine serum albumin and Ficoll).
Five mm EDTA, 0.75 M NaCl and 50 mM NaH2PO4 pH 8.3
and denatured salmon sperm DNA (250jgml-').
Filters were hybridised overnight under the same condi-
tions as for prehybridisation with the addition of
1-5 x 106 c.p.m. ml-' of denatured cDNA probe.
After hybridisation filters were washed with three changes
of 2 x SSC (20 x SSC = 3 M NaCl, 0.3 M trisodium citrate,
pH7), 0.1% SDS at room temperature and two changes of
0.1 x SSC, 0.1% SDS at 65°C. Autoradiography was carried
out using Hyperfilm MP (Amersham, UK) with intensifying
screens at -70°C for 4-14 days. To assess the degree of
loading of mRNA onto the membranes the membranes were
stripped by immersing in 0.1% SDS at 100°C for two hours.
Representative filters were then hybridised to the cDNA
probe to beta-Actin as described above to ensure that equal
loading of RNA had occurred.
Quantification of mRNA was carried out by comparison
with serial dilutions of the appropriate plasmid with a scale
of + + + + + to + as previously described. (Barrett-Lee et
al., 1987). For TGF-P, this was by densitometry while for
EGFR and TGF-a the low levels of RNA expression was
assessed visually.
Oestrogen receptor determination
Measurement of ER was by a modification of the dextran
coated charcoal assay (McGuire & De La Garza, 1973) or
alternatively for small samples ER was estimated by an
immunocytochemical assay as previously described (McClel-
land et al., 1986). Using the biochemical assay, carcinomas
with > 10 fmolmg-' were considered ER positive while with
the immunocytochemical assay, tumours with >25% stain-
ing were considered ER positive.
Table I Tumour characteristics related to growth factor expression
Tumour TGF-a TGF-p, EGFR
characteristics + ve -ve Low High + ve -ve
T stage TO 0 1 1 0 1 0
TI 7 4 9 23 4 5
T2 25 29 29 59 35 32
T3 10 9 9 14 6 9
T4 4 5 4 6 3 4
Tx 5 5 4 10 3 5
Node status No 22 24 20 58 20 27
NI 17 23 25 37 16 23
ER status -ve 14 18 18 26 10 25
+ ve 28 21 24 40 28 22
*P
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Figure 1 a, Relapse free survival related to TGF-P, expression.
b, Survival related to TGF-P, expression.
Statistical analysis
Comparison between subgroups was made with the Chi
squared test applying Yates correction were appropriate. Sur-
vival analysis was performed using the Log rank test on Life
tables. Stratified analysis was made using the Mantel-Cox
test on stratified data.
Results
The clinicopathological details of the patients correlated with
expression of TGF-pl, TGF-a and EGFR is shown in Table
I.
TGF-p,
TGF-P, mRNA was measured in 167 carcinomas by dot blot
analysis. All tumours contained detectable levels of the tran-
script. TGF-1, was highly expressed in most tumours. One
hundred and twelve tumours (67%) expressed high levels
(+ + + + or + + + + + +) while 55 expressed medium or
low levels. Northern analysis detected a 2.5 kb transcript.
The level of expression of TGF-P, was higher than the ex-
pression of TGF-a or EGFR. As there is evidence that
oestrogen might regulate the activity and the expression of
TGF beta the expression of TGF-P, was examined in relation
to ER status. ER status was known in 108 tumours and 64
(59%) were positive. No correlation of TGF-P, with ER
status was found (Chi2 = .03 P = .86). In 140 patients
pathological node status was known. 62 (44%) were node
positive. There was an inverse correlation of TGF-I, and
node status with high levels of TGF-P, associated with node
negativity (Chi2 = 3.41 P = 0.064). In 149 patients where
menstrual status was recorded there was no correlation of
TGF-P, levels with menstrual status (Chi2 = 0.01, P = 0.92).
There was no correlation of TGF-P1 with T stage. We also
i
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examined whether there was any correlation of TGF-P, ex-
pression with TGF-o or EGFR but no correlation was seen
(Data not shown).
The influence of TGF-P13 mRNA levels on relapse free
survival and survival was examined by life table analysis in
167 patients (Figure 1 a and b). The median follow up of
survivors was 60 months. Patients with high levels ofTGF-1,3
had a longer relapse free survival than patients with low
levels ofTGF-pl. The statistical difference in actuarial relapse
free survival over the whole period was not significant
P = 0.12 although the probability of relapse free survival at
80 months was prolonged in the patients with high TGF-P1
levels (P = 0.055). This suggestion of prolongation of relapse
free survival for patients with high TGF-P1 levels was
accounted for by the relationship with node status as when a
correction for node status was applied there was no correla-
tion of TGF-P, levels with relapse free survival (P = 0.54,
Mantel-Cox test).
TGFAlpha
TGF-o mRNA was measured in 104 tumours by dot blot
analysis. Transcripts of 4.8 and 2.2 kb were detected on
northern analysis. Levels of expression were low and were
scored as present or absent. Hybridisation signals of an
intensity less than + of the positive plasmid control were
scored as negative. Fifty-three (51%) tumours expressed
TGF-o mRNA. In 86 patients where pathological node status
was known there was no correlation seen with TGF-a expres-
sion (Chi2 = .43 P = 0.51). Similarly there was no correlation
with ER status in 81 patients where this was known.
There was no evidence that TGF-o mRNA levels had any














One hundred and six tumours were examined for EGFR
mRNA expression by dot-blot analysis. 55 (51%) had detec-
table levels which were scored as + or + +. Transcripts of
10.0, 6.4 and 4.8 kb were detected by Northern analysis. In
87 tumours the ER status was known and there was a
significant inverse correlation of EGFR positivity with ER
status. (Chi2 = 6.69 P = 0.018). No correlation was seen with
pathological nodal status in 86 patients where this was
known. From life table analysis there was no evidence from
this study in 107 patients with clinical follow up that EGFR
mRNA levels predicted either early relapse or death (Figure
3a and b). We found no evidence that co-expression of
TGF-a and EGFR was associated with a poor prognosis
(data not shown).
Discussion
This study has addressed the question as to whether the
expression (at the mRNA level) ofTGF-p1, TGF-a or EGFR
can have clinical significance. Both epidermal growth factor
and TGF-a cause proliferation of breast carcinoma cell in
vitro and several reports have indicated that levels of EGFR
are related to prognosis in breast cancer (Toi et al., 1990;
Lewis et al., 1990; Grimaux et al., 1989; Rios et al., 1988;
Sainsbury et al., 1987). Other studies have not confirmed this
(Foekens et al., 1989; Hawkins et al., 1991) and the exact
importance of EGFR levels in breast cancer as a prognostic
determinant remains controversial. Our study found an
inverse correlation of EGFR with ER status which confirms
the reports from other studies (Toi et al., 1990; Lewis et al.,
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Figure 2 a, Relapse free survival related to TGF-a expression. b,
Survival related to TGF-a expression.
Figure 3 a, Relapse free survival related to EGFR expression. b,
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al., 1988; Rios et al., 1988; Foekens et al., 1989). The correla-
tion with other tumour parameters noted by other workers
was not found in this study. A correlation with nodal status
(Bolufer et al., 1990), lymphatic invasion (Toi et al., 1990),
and tumour size (Sainsbury et al., 1988) has been noted
although results have not been consistent. The reason for the
discrepancies in the literature might be due to the relatively
small size of some of the samples or to differences in method-
ology of measuring EGFR. Most previous reports have used
a ligand binding assay of EGFR with varying levels of
cut-off defining EGFR positivity. It can be argued that levels
of mRNA might not correlate with EGFR protein levels and
this is the reason why no correlation with other parameters
has been noted. Although this is possible we have previously
shown a high degree of correlation between EGFR mRNA
as determined by dot-blot hybridisation and EGFR status as
determined by immunocytochemistry (Barrett Lee et al.,
1990). The same argument applies to the relationship
between mRNA expression and protein expression ofTGF-P,
and TGF-a but these are not clearly characterised.
As the major ligand for EGFR is TGF-a in breast cancer
it is of interest to speculate that tumour levels of TGF-a
might effect the natural history of the disease. Recently it has
been reported that high levels of TGF-x as measured
immunocytochemically correlates with a poor prognosis in
adenocarcinoma of the lung (Tateishi et al., 1991). Previous
investigators have examined TGF-a expression in small series
of patients with breast cancer and have found no evidence of
a correlation with ER status, node status or prognosis (Ciar-
diello et al., 1989; Bates et al., 1988). This is confirmed in our
series which is the largest series to date examining this ques-
tion.
Low levels of TGF-,B, mRNA were found to be associated
with node positivity and a shorter relapse free survival. TGF-
PI is a member of a family of peptides which are highly
conserved in nature and are multifunctional. TGF-PI is
generally inhibitory to epithelial cells in vitro and has several
effects on the regulation of extracellular matrix components
(Sporn & Roberts, 1989). TGF-,B increases the transcription
of the genes for collagen and fibronectin while it decreases
the secretion of members of the metalloproteinase family.
TGF-,B also increases the production of protease inhibitors
including plasminogen activator inhibitor and the tissue
inhibitors of metalloproteinase TIMPI and TIMP2. There is
accumulating evidence that the metastatic behaviour of a
tumour is strongly determined by its ability to breakdown
basement membrane possibly by the increased production of
collagenase (Liotta et al., 1991). It is likely that natural tissue
proteinase inhibitors would potentially inhibit this invasive
process. High levels of TGF-1, may protect against invasion
by locally regulating basement membrane components and
protease action. TGF-P1 is hormonally regulated in vitro and
several investigators have demonstrated that the anti-
oestrogen Tamoxifen increases the secretion of TGF-P3
(Knabbe et al., 1987; Colletta et al., 1990) suggesting that
this might be an important mediator in the mechanism of
endocrine therapy, possibly through the above mechanism.
The potential interplay between TGF-P3 and other
members of the TGF-P family in human breast cancer
together with the many known actions of this family of
growth factors argues against a simplistic explanation of the
role of TGF-P1 in this disease. However these data suggest
that further studies into the possible role of TGF-,B, as a
prognostic indicator or as a potential target for novel therapy
in breast cancer are warranted.
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